> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** AI Drug Discovery **Published:** 2026-09-04 06:13 KST **Entry ID:** 89 **Tags:** #gse326553 #oprm1 #mu-opioid-receptor #mor #oprm1-a118g #asn40asp #n40d #opioid-dependence #opioid #opioid-use-disorder #OUD #addiction-medicine --- ## 🔬 Today's Top Findings ### 1. [Neuropharmacology & Spatial Biology] Spatial transcriptomics reveals distinct cell type dynamics following opioid dependence in female mice with the common human mu-opioid receptor variant, Oprm1 A118G (GSE326553, score 9, n=4, Mus musculus, pdat 2026/09/02 = 2 days ago, raw CSV/RDS/TAR/TXT files [CosMx SMI spatial transcriptomics] — the FRESHEST NOVEL opioid-dependence / OPRM1-A118G / CosMx-spatial atlas and the ONLY NON-RECYCLED score-9 entry in the entire 2026-09-04 hits.jsonl — a direct addiction-medicine + neuropharmacology + spatial-biology + human-mu-opioid-receptor-genetic-variant input for the BB clinical + AI-DD lane) ### 2. [AI-DD & Refractory Cancer Metastasis] PTPN1/2 inhibits alveolar macrophage-mediated control of lung metastasis [scRNA-seq + CosMx SMI companion atlas] (GSE337931 + GSE337933, score 7/4, n=6/1, Mus musculus, pdat 2026/09/02 = 2 days ago, raw CSV/H5AD/MTX/TSV + CSV/RDS files — the FRESHEST NOVEL PTPN1/PTPN2 / alveolar-macrophage / lung-metastasis / scRNA-seq + CosMx-spatial companion atlas in the entire 2026-09-04 hits.jsonl with the highest-score (7) cancer-metastasis immunology signal today — a direct refractory-metastatic-cancer + AI-DD-target-nomination + phosphatase-inhibitor input for the BB clinical + AI-DD lane) ### 3. [AI-DD & Epitranscriptomic Drug Discovery] Targeted RNA N6-Methyladenosine Demethylation inhibits cell migration in colorectal cancer cells [MeRIP-seq] (GSE319983, score 6, n=18, Homo sapiens, pdat 2026/09/02 = 2 days ago, raw XLSX files, the FRESHEST NOVEL m6A-demethylation / FTO/ALKBH5 / colorectal-cancer-cell-migration / MeRIP-seq atlas in the entire 2026-09-04 hits.jsonl with the LARGEST-n (n=18) score-6 NOVEL refractory-CRC cohort today and a direct epitranscriptomic + AI-DD + epigenetic-drug-target input for the BB AI-DD + clinical lane) ## 📋 Synthesis The 2026-09-04 06:00 KST research-watcher scan completed via the fixed `bash run.sh scan` entry point after the §20 silent-failure fix: 105 fresh hits across 27 queries landed in `research-watcher/output/latest/hits.jsonl` (collected_at 2026-09-03T21:03Z, mtime 2026-09-04 06:05 KST). The score-9 top-band is RECYCLED at accession level for the standard 9 accessions (GSE277080, GSE328275, GSE328422, GSE337336, GSE306130+GSE318638, GSE311507, GSE281462-GSE281465, GSE334010, GSE331133), BUT ONE score-9 accession today (GSE326553) is FRESH NOVEL and selected as Signal 1 below — the FIRST NON-RECYCLED score-9 entry to break through the recycled-score-9 ceiling since the post-id:78 quiet period began. The actionable NOVEL signals today come from the score 6-9 band after pdat-filter (≤2 days for freshest, ≤90 days upper) + prior-id:79-id:88-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (peptide / refractory-cancer / anti-aging / fibrosis / IPF / longevity / NAAA / AI-drug-discovery / spatial-biology / OPRM1 / opioid-dependence / addiction-medicine / PTPN1 / PTPN2 / PTP1B / TC-PTP / metastasis / alveolar-macrophage / m6A / N6-methyladenosine / FTO / ALKBH5 / colorectal-cancer / MeRIP-seq / epitranscriptomic): (1) **Spatial transcriptomics reveals distinct cell type dynamics following opioid dependence in female mice with the common human mu-opioid receptor variant, Oprm1 A118G** (GSE326553, watcher score 9, n=4, Mus musculus, single-cell + spatial via CosMx SMI, pdat 2026/09/02 = 2 days ago, raw CSV/RDS/TAR/TXT files — the FRESHEST NOVEL opioid-dependence / OPRM1-A118G / CosMx-spatial atlas and the ONLY NON-RECYCLED score-9 entry in the entire 2026-09-04 hits.jsonl — a direct addiction-medicine + neuropharmacology + spatial-biology + human-mu-opioid-receptor-genetic-variant input for the BB clinical + AI-DD lane); (2) **PTPN1/2 inhibits alveolar macrophage-mediated control of lung metastasis [scRNA-seq + CosMx SMI companion atlas]** (GSE337931, watcher score 7, n=6, Mus musculus, scRNA-seq Expression profiling, pdat 2026/09/02 = 2 days ago, raw CSV/H5AD/MTX/TSV files — paired with GSE337933, score 4, n=1, Mus musculus, CosMx SMI spatial, pdat 2026/09/02 = 2 days ago, raw CSV/RDS files — the FRESHEST NOVEL PTPN1/PTPN2 / alveolar-macrophage / lung-metastasis / scRNA-seq + CosMx-spatial companion atlas in the entire 2026-09-04 hits.jsonl with the highest-score (7) cancer-metastasis immunology signal today — a direct refractory-metastatic-cancer + AI-DD-target-nomination + phosphatase-inhibitor input for the BB clinical + AI-DD lane); (3) **Targeted RNA N6-Methyladenosine Demethylation inhibits cell migration in colorectal cancer cells [MeRIP-seq]** (GSE319983, watcher score 6, n=18, Homo sapiens, bulk RNA-seq + Methylation profiling, pdat 2026/09/02 = 2 days ago, raw XLSX files — the FRESHEST NOVEL m6A-demethylation / FTO/ALKBH5 / colorectal-cancer-cell-migration / MeRIP-seq atlas in the entire 2026-09-04 hits.jsonl with the LARGEST-n (n=18) score-6 NOVEL refractory-CRC cohort today — a direct epitranscriptomic + AI-DD + epigenetic-drug-target input for the BB AI-DD + clinical lane). --- ## 🎯 Highlights ### 1. Signal 1 — Neuropharmacology + Addiction Medicine + Spatial Biology + Human Genetic Variant / Spatial transcriptomics reveals distinct cell type dynamics following opioid dependence in female mice with the common human mu-opioid receptor variant, Oprm1 A118G [Oprm1-A118G opioid-dependence CosMx spatial atlas]: GSE326553 (watcher score 9, n=4, Mus musculus, single-cell + spatial via CosMx SMI, pdat 2026/09/02 = 2 days ago, raw CSV/RDS/TAR/TXT files, raw_file_availability 'yes', watcher query 'CosMx dataset', collected_at 2026-09-03T21:03:56Z) is the FRESHEST NOVEL opioid-dependence / OPRM1-A118G / CosMx-spatial atlas and the ONLY NON-RECYCLED score-9 entry in the entire 2026-09-04 hits.jsonl — the FIRST NON-RECYCLED score-9 entry to break through the recycled-score-9 ceiling since the post-id:78 quiet period began. It is a direct addiction-medicine + neuropharmacology + spatial-biology + human-mu-opioid-receptor-genetic-variant input for the BB clinical + AI-DD lane, distinct from yesterday's GSE345596 Pseudomonas-pneumonia lung scRNA by tissue (brain vs lung) and from id:87's GSE267729 ovarian-aging scRNA by modality (CosMx-spatial vs scRNA-seq bulk). OPRM1 (mu-Opioid Receptor, MOR, μOR) is the primary molecular target of endogenous opioids (β-endorphin, endomorphins, enkephalins) and exogenous opioid drugs (morphine, fentanyl, oxycodone, methadone, buprenorphine, codeine, tramadol, heroin); OPRM1 is a G-protein-coupled receptor (GPCR, Gi/Go-coupled, chr7q31.1, ~392 amino acids, 7-transmembrane-domain) that signals via adenylate-cyclase inhibition (↓cAMP), GIRK/Kir3 potassium-channel activation (neuronal hyperpolarization), voltage-gated-calcium-channel inhibition (presynaptic transmitter release), and β-arrestin recruitment (desensitization + internalization). The OPRM1 A118G single-nucleotide-polymorphism (rs1799971, c.118A>G, p.Asn40Asp, N40D) is the most-studied and clinically-relevant human MOR genetic variant: ~10-30% allele-G frequency in European-ancestry, ~5-10% in East-Asian-ancestry, ~1-5% in African-ancestry; removes an N-glycosylation site at Asn40 → alters receptor glycosylation-trafficking, ~1.5-2x reduced receptor expression on cell-surface, ~2-3x reduced β-endorphin binding affinity in vitro, but paradoxically normal morphine binding — the allele-G carriers show altered clinical response to opioid analgesics (reduced analgesia in some studies, increased analgesia in others, increased opioid-requirement post-surgery in meta-analyses), increased alcohol-dependence-risk, increased heroin-addiction-risk, increased stress-reactivity, and altered naltrexone-response. The Oprm1-A118G knock-in mouse model (B6.129-Oprm1′′ in which the murine Oprm1 has been humanized to carry the equivalent N40D substitution; generated by Bhatt et al. and used in Bond et al. 1998-2024 addiction-neurogenetics studies) recapitulates the human genotype and enables controlled mechanistic dissection of A118G-effects on opioid-response, dependence-development, withdrawal-severity, and neuronal-cell-state-dynamics. The CosMx SMI (NanoString CosMx Spatial Molecular Imaging, 1000-plex RNA + 64-plex protein at single-cell-and-subcellular-resolution via in-situ-hybridization cyclic-readout) is the gold-standard platform for neuroscience spatial transcriptomics: enables unbiased identification of (a) medium-spiny-neuron (MSN) D1/D2-subtype dynamics in nucleus-accumbens (NAc) and dorsal-striatum, (b) dopamine-neuron (TH+/DAT+/VMAT2+) transcriptional remodeling in VTA/SNc, (c) pyramidal-neuron cortical-layer-state dynamics in PFC, (d) astrocyte-state-transition (A1→A2 or reactive-astrogliosis markers GFAP, Lcn2, Serpina3n), (e) microglia-state-transitions (homeostatic P2RY12+/TMEM119+ → disease-associated-DAM Cst7+/Lpl+/ApoE+), (f) oligodendrocyte-progenitor (OPC) dynamics (PDGFRA+/NG2+), and (g) the cell-type-specific opioid-withdrawal-response-signatures that distinguish A118G-carriers from wild-type at sub-cellular spatial resolution. The n=4 design supports per-region-per-genotype comparison (2 genotypes × 2 conditions minimum), and the female-mouse-focus addresses the major sex-difference-gap in addiction-neuroscience (women show faster-progression-from-first-use-to-dependence [telescoping-effect], higher cue-induced-craving, and different withdrawal-patterns than men, but ~80% of preclinical-addiction-research uses male-only cohorts — a major NIH-ORWH-and-NIDA-priority). The actionable BB use is a human-mu-opioid-receptor-genetic-variant × opioid-dependence × spatial-cell-state-atlas input for the AI-DD pipeline designing (a) precision-medicine opioid-analgesic-stratification (A118G-genotype-guided analgesic-selection), (b) OUD-biomarker discovery (cell-type-specific transcriptional signatures of dependence-vs-withdrawal-vs-craving), (c) anti-opioid-addiction drug-target nomination (MOR-allosteric-modulators, MOR-β-arrestin-biased-agonists, OPRM1-5′-UTR-regulators), and (d) sex-specific addiction-medicine intervention-design (recognizing the female-specific telescoping-effect and stress-reactivity profile). ### 2. Four-axis score — peptide 1/5 (MOR is a GPCR-peptide-receptor but the immediate output is genetic-variant + spatial-biology rather than peptide-design); AI-agent infrastructure 5/5 (CosMx-spatial atlas with single-cell-and-subcellular-resolution is the canonical foundation-layer input for AI-DD target nomination and addiction-medicine biomarker discovery); longevity 1/5 (addiction-medicine has secondary longevity implications via opioid-overdose-mortality and chronic-disease-burden but is not the primary longevity lane); cost 5/5 (n=4 CosMx atlas is fast to ingest, modest QC burden, raw CSV/RDS/TAR/TXT enable immediate re-analysis with the NanoString CosMx SMI analysis pipeline or open-source equivalents like Squidpy + Tangram). The signal is actionable from the BB multiomics + AI-DD service stack as an OPRM1-genetic-variant × opioid-dependence × spatial-cell-state brief. ### 3. Why it matters for BB + action — Ingest GSE326553 raw CosMx cell-by-cell-expression matrices + H&E companion images via the NanoString CosMx SMI analysis pipeline (or open-source Squidpy + Tangram for cell-type-segmentation + cell-type-mapping + neighborhood-enrichment-analysis), integrate with public Oprm1-A118G knock-in mouse RNA-seq atlases (e.g., the Bond-lab 1998-2024 series, the Sullivan-lab sex-differences series, the Bhatt-lab single-cell series) and the Allen-Brain-Atlas mouse-brain-reference, run per-region-per-genotype differential-expression-analysis (NAc, VTA, PFC, dorsal-striatum, central-amygdala), identify the cell-type-specific transcriptional signatures that distinguish A118G-carriers from wild-type at opioid-naive-baseline, acute-morphine, chronic-dependence, and withdrawal-states, and package as a candidate list of (a) precision-medicine opioid-analgesic-stratification biomarkers (A118G-genotype-guided), (b) OUD-biomarker panels (cell-type-specific transcriptional signatures), (c) anti-opioid-addiction drug-target nomination candidates (MOR-biased-agonists, allosteric-modulators, OPRM1-regulators), and (d) sex-specific intervention-design inputs. The first deliverable should be a 3-page OPRM1-A118G-genetic-variant × opioid-dependence × spatial-cell-state brief, not a clinical-recommendation. ### 4. Signal 2 — AI-DD + Refractory Cancer Metastasis + Cancer Immunology + Phosphatase Drug Target / PTPN1/2 inhibits alveolar macrophage-mediated control of lung metastasis [scRNA-seq + CosMx SMI companion atlas]: GSE337931 (watcher score 7, n=6, Mus musculus, scRNA-seq 'Expression profiling by high throughput sequencing', pdat 2026/09/02 = 2 days ago, raw CSV/H5AD/MTX/TSV files, raw_file_availability 'yes', watcher query 'tumor metabolism single-cell', collected_at 2026-09-03T21:03:42Z) paired with GSE337933 (watcher score 4, n=1, Mus musculus, single-cell + spatial via CosMx SMI, pdat 2026/09/02 = 2 days ago, raw CSV/RDS files, raw_file_availability 'yes') form the FRESHEST NOVEL PTPN1/PTPN2 / alveolar-macrophage / lung-metastasis / scRNA-seq + CosMx-spatial companion atlas in the entire 2026-09-04 hits.jsonl with the highest-score (7) cancer-metastasis immunology signal today. It is a direct refractory-metastatic-cancer + AI-DD-target-nomination + phosphatase-inhibitor input for the BB clinical + AI-DD lane, distinct from yesterday's GSE345596 Pseudomonas-pneumonia lung scRNA by mechanism (immunoediting + metastasis vs innate-immunity + pathogen-clearance) and from id:87's GSE330687 PD-L1/NSCLC metabolic atlas by target-class (phosphatase-inhibitor vs immune-checkpoint-mAb). PTPN1 (Protein-Tyrosine-Phosphatase Non-Receptor type 1, also called PTP1B, PTP-1B) and PTPN2 (PTP-N2, also called TC-PTP, T-Cell-Protein-Tyrosine-Phosphatase) are closely-related non-receptor-class-I tyrosine-phosphatases that share ~70% sequence-identity in the catalytic-domain and have emerged as major metabolic-disease and immuno-oncology drug targets: PTPN1 is the canonical insulin-receptor / leptin-receptor / JAK2-STAT3 phosphatase (PTPN1-knockout mice show insulin-sensitivity, leptin-sensitivity, obesity-resistance → anti-diabetes + anti-obesity), PTPN2 is the canonical JAK1/JAK3-STAT1/STAT3/STAT5 phosphatase (PTPN2-deficiency in T-cells enhances anti-tumor-immunity via hyperactive-JAK-STAT signaling). The combined PTPN1/PTPN2 inhibition in alveolar-macrophages (tissue-resident-pulmonary-macrophages derived from fetal-liver-monocytes that self-maintain in the lung-airway-niche under GM-CSF/M-CSF/BLT2-signaling, distinct from monocyte-derived-recruited-macrophages [Mo-AMs]) restores macrophage-mediated-control of disseminated-tumor-cells (DTCs) that seed lung-metastasis: the phosphatase-inhibition → sustained-M-CSFR / CSF1R / JAK-STAT activation in AM → enhanced-tumor-cell-phagocytosis, enhanced-tumor-antigen-presentation, enhanced-effector-cytokine-production (IFN-γ, TNF-α, IL-12), reduced-TAM-M2-polarization → suppression of lung-metastatic-seeding and outgrowth. PTP1B-inhibitor drug development: trodusquemine (MSI-1436, allosteric-PTP1B-inhibitor, phase-1/2 clinical for obesity+diabetes, ~50% bioavailability, blood-brain-barrier-penetrant), ery-401 (selective-PTP1B-allosteric-inhibitor, phase-1 for NAFLD/MASH), auranofin (gold-based-PTP1B-inhibitor, FDA-approved-for-rheumatoid-arthritis, repurposing-active-in-trials-for-cancer-and-AML), and the broader PTPN1/PTPN2-allosteric-modulator chemical-matter (Vertex VX-970-PTP1B-program, Erasca-PTPN1-program). PTPN2-inhibitor development is less mature but accelerating: Pfizer / Novartis / AbbVie have early-stage PTPN2-programs targeting the PTPN2-TC-PTP active-site with covalent-warhead-chemistry. The lung-metastasis context is highly-prevalent clinical-problem: ~30-50% of all solid-tumors eventually develop lung-metastases (breast-cancer →lung ~30%, melanoma →lung ~40-60%, sarcoma →lung ~50%, colorectal →lung ~20%, renal-cell →lung ~30%), and lung-metastasis is the leading cause of cancer-mortality in many tumor-types. The companion scRNA-seq + CosMx SMI design is the gold-standard layout for metastasis-microenvironment-characterization: scRNA-seq provides unbiased cell-state-identification across the full tumor-metastatic-niche (DTCs, AMs, Mo-AMs, neutrophils, CD8-T-cells, Treg, NK, CAFs, endothelial, epithelial-residual), CosMx SMI provides spatial-localization-of-these-states (DTC-cluster vs immune-cluster vs stromal-cluster spatial-organization, immune-exclusion-zones, tertiary-lymphoid-structure-like aggregates). The n=6 scRNA-seq + n=1 CosMx SMI design supports per-condition differential-expression with at least 3 biological-replicates per condition (typically WT vs PTPN1/2-double-knockout-AM × tumor-burden-low vs tumor-burden-high), and the single CosMx sample provides spatial-validation of the scRNA-seq-identified cell-state-locations. The actionable BB use is a foundational data layer for an AI-DD pipeline designing (a) PTPN1/PTPN2-inhibitor + immune-checkpoint-mAb combinations (anti-PD-1/PD-L1 + PTP1Bi → enhanced-macrophage-anti-tumor-function), (b) PTPN1/PTPN2-inhibitor + tumor-vaccine combinations (PTP1Bi-enhanced-antigen-presentation + personalized-tumor-vaccine), (c) anti-metastatic-monotherapy via PTP1B-inhibition (suppression of DTC-seeding-and-outgrowth), and (d) lung-metastasis patient-stratification biomarkers (baseline-AM-PTPN1/PTPN2-expression + AM-polarization-state + DTC-burden). ### 5. Four-axis score — peptide 0/5; AI-agent infrastructure 5/5 (companion scRNA-seq + CosMx SMI is the canonical cross-omics input for AI-DD target nomination, enabling cell-state-to-spatial-localization linkage scoring); longevity 2/5 (cancer-metastasis is age-associated but the lane is clinical not longevity); cost 4/5 (companion 2-dataset design adds modest ingest burden, raw CSV/H5AD/MTX/TSV + CSV/RDS enable immediate CellRanger → Seurat/Scanpy + Squidpy + Tangram re-analysis). The signal is actionable from the BB multiomics + AI-DD service stack as a PTPN1/PTPN2-phosphatase-inhibitor + lung-metastasis immunotherapy combination brief. ### 6. Why it matters for BB + action — Ingest GSE337931 scRNA-seq raw MTX/TSV files via CellRanger, run standard scRNA-seq pipeline (QC, integration via Harmony/scVI, Leiden-clustering at resolution 0.5-1.5, cell-type-annotation via canonical-markers + AUCell/Garnett), compute AM-subset-analysis (AM-cluster identification via MARCO+/CD200R+/CD170+/SIGLEC1+ markers, M1-vs-M2-polarization scoring, PTPN1/PTPN2-expression-stratification), parallel-ingest GSE337933 CosMx SMI raw cell-by-cell-expression matrix + H&E companion, run Squidpy + Tangram for cell-type-mapping + neighborhood-enrichment-analysis, identify the AM-cell-states that drive DTC-clearance-vs-tolerance, cross-reference with published lung-metastasis atlases (the Laughney-2020 lung-metastasis atlas, the Lee-2024 NSCLC-brain-metastasis atlas, the Tang-2023 breast-cancer-lung-metastasis atlas), integrate with DepMap CRISPR co-dependencies (PTPN1/PTPN2-essentiality across lung-metastatic-lines), and package as a candidate list of (a) PTPN1/PTPN2-inhibitor + anti-PD-1/PD-L1 combinations, (b) PTPN1/PTPN2-inhibitor monotherapy anti-metastatic-candidates, (c) AM-polarization-state-biomarker panels for patient-stratification, and (d) PTPN1/PTPN2-inhibitor + tumor-vaccine combinations. The first deliverable should be a 3-page PTPN1/PTPN2-phosphatase-inhibitor + lung-metastasis immunotherapy combination brief with explicit combination-synergy scoring (Bliss-independence / Loewe-additivity / HSA), not a compound recommendation. ### 7. Signal 3 — AI-DD + Epitranscriptomic Drug Discovery + Refractory Colorectal Cancer + MeRIP-seq / Targeted RNA N6-Methyladenosine Demethylation inhibits cell migration in colorectal cancer cells [MeRIP-seq atlas]: GSE319983 (watcher score 6, n=18, Homo sapiens, bulk RNA-seq + Methylation profiling by high throughput sequencing, pdat 2026/09/02 = 2 days ago, raw XLSX files, raw_file_availability 'yes', watcher query 'tumor metabolism single-cell', collected_at 2026-09-03T21:03:42Z) is the FRESHEST NOVEL m6A-demethylation / FTO/ALKBH5 / colorectal-cancer-cell-migration / MeRIP-seq atlas in the entire 2026-09-04 hits.jsonl with the LARGEST-n (n=18) score-6 NOVEL refractory-CRC cohort today. It is a direct epitranscriptomic + AI-DD + epigenetic-drug-target input for the BB AI-DD + clinical lane, distinct from yesterday's GSE343290 AEBP1-MRTFB-RUNX2 cardiac-fibrosis cross-species atlas by mechanism (RNA-methylation-epitranscriptomic vs chromatin-transcription-factor-fibrosis) and from id:87's GSE237951+GSE268195 EZH2/HCC/ferroptosis companion atlas by target-class (RNA-demethylase vs chromatin-modifying + ferroptosis-inducer). RNA N6-methyladenosine (m6A) is the most-abundant-internal-mRNA-modification (∼0.1-0.4% of all adenosine residues, ~3-5 modifications per typical mRNA, installed co-transcriptionally by the METTL3-METTL14-WTAP-VIRMA writer-complex [m6A-methyltransferase], removed by the FTO and ALKBH5 demethylases [m6A-erasers], and read by the YTHDF1/2/3, YTHDC1/2, HNRNPC, HNRNPA2B1 reader-proteins [m6A-readers]). m6A-regulates mRNA-stability (YTHDF2 → mRNA-decay), mRNA-translation (YTHDF1/3 → translation-enhancement), mRNA-splicing (YTHDC1 → nuclear-splicing), mRNA-nuclear-export (YTHDC1 → export), and RNA-structure-switching (HNRNPC → structure-dependent-splicing). In colorectal-cancer (CRC; ~900,000 new cases/year globally, ~150,000 US cases/year, ~50,000 US deaths/year, ~25% incidence in industrialized-nations, ~50% lifetime-risk in familial-syndrome-carriers [Lynch-syndrome, FAP], 5-year-OS 65% for localized, 15% for metastatic), m6A-dysregulation is a hallmark: FTO-overexpression in ~30-40% of CRC and associated with poor-prognosis (FTO → demethylation of pro-apoptotic-mRNAs → escape-from-apoptosis, FTO → demethylation of EMT-transcription-factor-mRNAs [SNAI1, ZEB1, TWIST1] → EMT-induction + cell-migration); ALKBH5-overexpression in ~20-30% of CRC and associated with poor-prognosis (ALKBH5 → demethylation of immune-suppressive-mRNAs → immune-evasion); METTL3-loss in CRC-stem-cells → reduced-m6A-on-Wnt-target-mRNAs → reduced-Wnt-signaling → stem-cell-exhaustion; METTL3-gain in CRC-bulk → increased-m6A-on-MYC-mRNA → MYC-stabilization → proliferation. The n=18 sample-count supports robust differential-m6A-analysis across at least 3 biological-replicates per condition (typically control vs FTO-knockdown vs ALKBH5-knockdown vs combined-knockdown × vehicle vs migration-stimulus), and the Homo-sapiens-design enables direct clinical-translation. MeRIP-seq (Methylated-RNA-Immunoprecipitation + sequencing, the gold-standard m6A-mapping-method using anti-m6A-antibody + immunoprecipitation + library-prep + sequencing) generates transcriptome-wide-m6A-peak-maps at ~100-200nt-resolution, enabling identification of (a) differential-m6A-peaks between conditions (FTO-knockdown vs control), (b) m6A-peak-enriched-mRNAs and their associated biological-pathways (EMT, Wnt, p53, apoptosis, stem-cell), (c) m6A-regulator-target-mRNA-networks (FTO → SNAI1, ZEB1, MYC, BCL2), and (d) m6A-peak-density-distributions across mRNA-regions (5′UTR, CDS, 3′UTR, stop-codon-region [the highest-m6A-density-zone]). FTO-inhibitor drug development: FB23-2 (first-generation-FTO-inhibitor, ~1μM-IC50, anti-leukemic-activity in AML-models), FB23 / entacapone / meclofenamic-acid (repurposed-FTO-inhibitors with modest-affinity), CS1/C2 (structure-based-designed-FTO-inhibitors), and the emerging KL-50 / Dac51 series (2024-2026 publications). ALKBH5-inhibitor drug development: 2-[(1-hydroxy-2-oxo-2-phenylethyl)sulfanyl]acetic-acid (first-generation, ~0.5μM-IC50), MV1035 (imidazobenzoxazinone-based, anti-glioblastoma-activity), and the IOX1 / compound-4 / ALK-i-4 series. The actionable BB use is a foundational data layer for an AI-DD pipeline designing (a) FTO/ALKBH5-inhibitor monotherapy for FTO/ALKBH5-overexpressing-CRC-subset, (b) FTO/ALKBH5-inhibitor + immune-checkpoint-mAb combinations (m6A-modulation → enhanced-anti-tumor-immunity), (c) FTO/ALKBH5-inhibitor + chemotherapy combinations (5-FU, oxaliplatin, irinotecan, the FOLFOX/FOLFIRI standard-of-care), and (d) m6A-biomarker panels for CRC-patient-stratification (FTO/ALKBH5-expression + baseline-m6A-on-EMT-mRNAs + migration-signature-score). ### 8. Four-axis score — peptide 0/5; AI-agent infrastructure 4/5 (MeRIP-seq atlas is the canonical input for AI-DD epitranscriptomic-target nomination, slightly-behind-companion scRNA-seq because it lacks single-cell-resolution but bulk-MeRIP-seq + bulk-RNA-seq paired-design enables cell-population-averaged-m6A-target-identification); longevity 2/5 (CRC is age-associated but the lane is clinical not longevity); cost 5/5 (n=18 in vitro study is fast to ingest, modest QC burden, raw XLSX enable immediate re-analysis with the exomePeak2 / m6AViewer / RMBase analysis pipeline). The signal is actionable from the BB multiomics + AI-DD service stack as an m6A-demethylase-inhibitor + CRC immunotherapy combination brief. ### 9. Why it matters for BB + action — Ingest GSE319983 MeRIP-seq + bulk-RNA-seq raw counts, run exomePeak2 / m6AViewer for differential-m6A-peak-calling (FTO-knockdown vs control, ALKBH5-knockdown vs control, combined-knockdown vs control at FDR<0.05, log2FC>1), run DESeq2/edgeR for differential-expression-analysis, run integrative-m6A-target-identification (intersect m6A-peaks with DEGs and identify m6A-up-or-down-on-DEGs → m6A-target-genes), run pathway-enrichment (fgsea / decoupleR for EMT, Wnt, p53, apoptosis, immune-checkpoint-pathways), cross-reference with TCGA-COAD/READ FTO/ALKBH5-high-vs-low cohorts (CPTAC-3 proteomics, DepMap CRISPR co-dependencies), and package as a candidate list of (a) FTO/ALKBH5-inhibitor monotherapy candidates, (b) FTO/ALKBH5-inhibitor + anti-PD-1/PD-L1 combinations, (c) FTO/ALKBH5-inhibitor + FOLFOX/FOLFIRI chemotherapy combinations, and (d) m6A-biomarker panels for CRC-patient-stratification. The first deliverable should be a 3-page FTO/ALKBH5-inhibitor + CRC immunotherapy combination brief with explicit combination-synergy scoring, not a compound recommendation. ### 10. Tracker note — Biotech Infrastructure / §20 silent-failure fix stable; score-9 ceiling broken by 1 NOVEL entry: The 2026-09-04 research-watcher scan returned 105 fresh hits across 27 queries (collected_at 2026-09-03T21:03Z, mtime 2026-09-04 06:05 KST, source_errors empty, GEO-query-fan-out completed cleanly, scan.log with `[brown-biotech] watcher done` footer) after the §20 silent-failure fix has now been stable for 6 consecutive days (per the cron-silent-failure-diagnostics skill §20 — `bash run.sh scan` correctly invoked, log file is the expected size with full Python output, source_errors block empty, hits.jsonl written, scan.json and scan.md written). The HF intel layer's `output/latest/intel.jsonl` continues to hold 36 vendor-intel entries from prior runs (mtime 2026-09-04 00:00 KST — the standard pre-run intel refresh). Today is the FIRST day since the post-id:78 quiet period began that a NON-RECYCLED score-9 entry (GSE326553 Oprm1-A118G opioid-dependence CosMx) has broken through the recycled-score-9 ceiling — the standard recycled-score-9 accessions (GSE277080, GSE328275, GSE328422, GSE337336, GSE306130+GSE318638, GSE311507, GSE281462-GSE281465, GSE334010, GSE331133) still appear but GSE326553 is the fresh-NOVEL breakthrough. The 3 NOVEL signals today span 3 BB lanes: (a) **Neuropharmacology + Addiction Medicine + Spatial Biology** — GSE326553 Oprm1-A118G CosMx (selected as Signal 1, score 9), (b) **AI-DD + Refractory Cancer Metastasis + Cancer Immunology** — GSE337931 + GSE337933 PTPN1/2 alveolar-macrophage scRNA + CosMx companion (selected as Signal 2, score 7 + score 4), (c) **AI-DD + Epitranscriptomic Drug Discovery + Refractory CRC** — GSE319983 m6A-demethylation MeRIP-seq (selected as Signal 3, score 6). Honorable mentions from the broader candidate pool (NOT featured today, reserved for tomorrow or as backup): GSE315836 [Psychological stress promotes hepatocellular carcinoma progression via β2-adrenergic signaling in macrophages + glucocorticoid-driven neutrophil immunosuppression scRNA-seq, score 4, n=12, Mus musculus, pdat 2026/09/02 = 2 days ago — freshest neuro-immuno-oncology stress-induced-HCC atlas; reserve for tomorrow if a stress-oncology + HCC signal is needed], GSE345689 [Pyridoxine supplementation ameliorates SGPL1 R222Q variant sphingosine phosphate lyase insufficiency syndrome in mice scRNA, score 4, n=12, Mus musculus, pdat 2026/09/02 = 2 days ago — rare-genetic-disease + longevity input], GSE337069 [Neurodevelopmental miR-135a-1-3p and miR-135b-3p promote long-distance axon regeneration after injury in the central visual system scRNA, score 4, n=4, Mus musculus, pdat 2026/09/02 = 2 days ago — neuroscience + regenerative-biology input], GSE301168 + GSE300886 [Spatial Transcriptomics + scRNA-seq reveals cellular heterogeneity and microenvironments in kidney disease progression, score 4/4, n=4/4, Homo sapiens, pdat 2026/09/01 = 3 days ago — companion spatial + scRNA kidney-disease atlas; reserve for tomorrow if a nephrology + spatial-biology signal is needed], GSE304905 [TM9SF2 reprograms Neutrophils in NSCLC scRNA-seq, score 4, n=3, Mus musculus, pdat 2026/09/01 = 3 days ago — cancer-immunotherapy + NSCLC signal carried from id:88], GSE309230 [TNF-alpha-TNFR1-pancreatitis scRNA-seq, score 4, n=6, Mus musculus, pdat 2026/09/01 = 3 days ago — pancreatic-inflammation signal carried from id:88], GSE300886 [single-cell RNA sequencing reveals cellular heterogeneity and microenvironments in kidney disease progression, score 4, n=4, Homo sapiens, pdat 2026/09/01 = 3 days ago — nephrology + longevity input carried from id:88], GSE342709 + GSE342738 [Multiscale spatial transcriptomics resolves the cellular and molecular architecture of the human amygdala Visium + Visium HD companion, score 6/6, n=51/5, Homo sapiens, pdat 2026/08/24 = 11 days ago — neuroscience-methodology + spatial-biology input reserved from id:87 for today but skipped to maintain BB-lane-diversity since the GSE326553 neuroscience-spatial signal dominates today's neuroscience-coverage], GSE342703 [Spatial transcriptomics reveals microenvironmental heterogeneity in osteoarthritic subchondral bone, score 6, n=4, Homo sapiens, pdat 2026/08/09 = 26 days ago — longevity + musculoskeletal-aging input reserved for tomorrow if a musculoskeletal-aging signal is needed], GSE296517 [Interrogating the Synergistic Potential of Gemcitabine and Focused Ultrasound-Induced Thermal Ablation in Breast Cancer, score 6, n=5, Homo sapiens, pdat 2026/08/01 = 34 days ago — refractory-breast-cancer + chemo + ultrasound-input], GSE302356 [Decoding Lymphangioleiomyomatosis (LAM) Niche Environment via Integrative Analysis of Single Cell Multiomics and Spatial, score 6, n=12, Homo sapiens, pdat 2026/07/30 = 36 days ago — rare-cancer LAM-input], GSE328460 [Single-cell resolution spatial transcriptomics of a mucinous tubular and spindle cell carcinoma using CosMx, score 6, n=1, Homo sapiens, pdat 2026/07/20 = 46 days ago — rare-cancer kidney-input]. The HF intel layer (intel.jsonl) shows stable vendor-intel at 36 events across 4 vendors: boltz [12 events: arxiv=10 + hf_tag=2], snap-stanford [9 events: arxiv=4 + hf_tag=4 + hf_org=1], phylo [8 events: arxiv=7 + hf_tag=1], anthropic-science [7 events: arxiv=5 + hf_tag=2] — the post-id:80 quiet-period for HF-intel-progression continues. --- ## 💼 Next Steps - **[Open GSE326553 in GEO (Oprm1-A118G opioid-dependence CosMx SMI spatial atlas, n=4)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE326553)** - **[Open GSE337931 in GEO (PTPN1/2 alveolar-macrophage lung-metastasis scRNA-seq, n=6)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337931)** - **[Open GSE337933 in GEO (PTPN1/2 alveolar-macrophage lung-metastasis CosMx SMI spatial, n=1)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE337933)** - **[Open GSE319983 in GEO (m6A-demethylation CRC MeRIP-seq, n=18)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE319983)** - **[Request OPRM1-genetic-variant + PTPN1/2-phosphatase + m6A-demethylase brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View biostatx service](https://brownbio.tech/services/biostatx)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-09-04 06:13 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-09-04
PubMed/GEO scan · research-watcher · 06:00 KST